ArticleCancer biology & therapy2019

Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.

Yangwei Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.